Never Miss Important Company Updates Again
Get AI-powered summaries of SEC filings delivered to your inbox
Follow your favorite stocks and get email alerts when they release important updates. Completely free.
Viridian Therapeutics is a biopharmaceutical company developing innovative biologic medicines for serious and rare diseases, primarily focusing on thyroid eye disease (TED). Its pipeline includes monoclonal antibodies targeting IGF-1R and engineered FcRn inhibitors to improve efficacy, safety, and convenience. The company aims to address unmet medical needs, advance clinical trials globally, and secure regulatory approvals for differentiated therapies in autoimmune and ophthalmic conditions.
This description was generated via AI from an annual report. Updated about 1 year ago.